Lepercq De Neuflize Asset Management LLC An2 Therapeutics, Inc. Transaction History
Lepercq De Neuflize Asset Management LLC
- $103 Billion
- Q1 2025
A detailed history of Lepercq De Neuflize Asset Management LLC transactions in An2 Therapeutics, Inc. stock. As of the latest transaction made, Lepercq De Neuflize Asset Management LLC holds 23,234 shares of ANTX stock, worth $24,628. This represents 0.03% of its overall portfolio holdings.
Number of Shares
23,234Holding current value
$24,628% of portfolio
0.03%Shares
1 transactions
Others Institutions Holding ANTX
# of Institutions
38Shares Held
13.7MCall Options Held
0Put Options Held
0-
Bml Capital Management, LLC Zionsville, IN5.75MShares$6.09 Million6.33% of portfolio
-
Almitas Capital LLC Santa Monica, CA1.31MShares$1.39 Million1.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.04MShares$1.1 Million0.0% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA1MShares$1.06 Million0.0% of portfolio
-
Peapod Lane Capital LLC Bedford Hills, NY581KShares$615,7040.89% of portfolio
About AN2 Therapeutics, Inc.
- Ticker ANTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 19,402,700
- Market Cap $20.6M
- Description
- AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menl...